Here’s an interesting new factoid about obesity: The world’s population has 17 million tons worth of extra fat. And almost one-third of that is from the U.S. alone, despite the fact that it only holds 5 percent of the population. That’s according to a new report published in BMC Public Health about obesity’s threat to the food supply. That’s is fueling a vibrant obesity treatment market, which is seeing an increasing number of new startups emerge, especially in the minimally invasive surgery and mobile health arenas.
Who’s the biggest of the big? By 2018, Novartis will edge out competitors Pfizer and Sanofi to become the top-selling drug company, predicts a new EvaluatePharma report. Gilead Sciences will be the Top 20′s biggest mover, the report says, due to its strong HIV franchise and its hepatitis C candidate acquired through its Pharmasset acquisition.
